Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update

Key Points

• Kalaris Therapeutics Inc. experienced a dramatic increase in short interest of 176.3% in September, reaching 516,700 shares, which is 10.0% of its total shares.
• An institutional investor, XTX Topco Ltd, has acquired a new position in Kalaris Therapeutics with 24,234 shares valued at approximately $65,000.
• Analysts have set a consensus price target of $3.00 for Kalaris Therapeutics, with ratings varying from "strong-buy" to "sell," indicating mixed opinions on the stock's future performance.

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 516,700 shares, a growth of 176.3% from the August 31st total of 187,000 shares. Based on an average trading volume of 269,500 shares, the days-to-cover ratio is presently 1.9 days. Currently, 10.0% of the shares of the stock are sold short. Currently, 10.0% of the shares of the stock are sold short. Based on an average trading volume of 269,500 shares, the days-to-cover ratio is presently 1.9 days.

Institutional Trading of Kalaris Therapeutics

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd purchased a new position in Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned approximately 0.13% of Kalaris Therapeutics at the end of the most recent reporting period. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on KLRS shares. Piper Sandler set a $3.00 target price on shares of Kalaris Therapeutics and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Raymond James Financial initiated coverage on Kalaris Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating for the company. Weiss Ratings restated a "sell (e)" rating on shares of Kalaris Therapeutics in a report on Saturday, September 27th. Finally, Wall Street Zen raised shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $3.00.

Kalaris Therapeutics Stock Down 6.3%

NASDAQ:KLRS traded down $0.45 during trading hours on Friday, hitting $6.64. The company had a trading volume of 111,743 shares, compared to its average volume of 123,997. The company's 50-day simple moving average is $3.79. Kalaris Therapeutics has a 52 week low of $2.14 and a 52 week high of $24.15.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.